AU2018238422B2 - Gene therapy for the treatment of CNGB1-linked retinitis pigmentosa - Google Patents

Gene therapy for the treatment of CNGB1-linked retinitis pigmentosa Download PDF

Info

Publication number
AU2018238422B2
AU2018238422B2 AU2018238422A AU2018238422A AU2018238422B2 AU 2018238422 B2 AU2018238422 B2 AU 2018238422B2 AU 2018238422 A AU2018238422 A AU 2018238422A AU 2018238422 A AU2018238422 A AU 2018238422A AU 2018238422 B2 AU2018238422 B2 AU 2018238422B2
Authority
AU
Australia
Prior art keywords
leu
glu
ala
ser
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018238422A
Other languages
English (en)
Other versions
AU2018238422A1 (en
Inventor
Martin Biel
Stylianos MICHALAKIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2018238422A1 publication Critical patent/AU2018238422A1/en
Application granted granted Critical
Publication of AU2018238422B2 publication Critical patent/AU2018238422B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2018238422A 2017-03-21 2018-03-21 Gene therapy for the treatment of CNGB1-linked retinitis pigmentosa Active AU2018238422B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762474409P 2017-03-21 2017-03-21
US62/474,409 2017-03-21
PCT/IB2018/051905 WO2018172961A1 (en) 2017-03-21 2018-03-21 Gene therapy for the treatment of cngb1-linked retinitis pigmentosa

Publications (2)

Publication Number Publication Date
AU2018238422A1 AU2018238422A1 (en) 2019-10-03
AU2018238422B2 true AU2018238422B2 (en) 2025-04-03

Family

ID=62044771

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018238422A Active AU2018238422B2 (en) 2017-03-21 2018-03-21 Gene therapy for the treatment of CNGB1-linked retinitis pigmentosa

Country Status (10)

Country Link
US (2) US12246072B2 (enExample)
EP (1) EP3600446A1 (enExample)
JP (1) JP7257377B2 (enExample)
CN (1) CN111050805A (enExample)
AR (1) AR111188A1 (enExample)
AU (1) AU2018238422B2 (enExample)
CA (1) CA3056211A1 (enExample)
TW (1) TW201902911A (enExample)
UY (1) UY37636A (enExample)
WO (1) WO2018172961A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220175969A1 (en) * 2019-03-04 2022-06-09 University Of Florida Research Foundation, Incorporated Enhanced human opsin promoter for rod specific expression
WO2020182722A1 (en) * 2019-03-08 2020-09-17 Universite Paris-Saclay Improved therapeutic method for rare ocular diseases by gene replacement
CN110241202A (zh) * 2019-06-25 2019-09-17 复旦大学附属眼耳鼻喉科医院 视网膜色素变性突变位点及其应用
JP2022549138A (ja) 2019-09-18 2022-11-24 インターガラクティック セラピューティクス インコーポレイテッド 合成ｄｎａベクターおよびその使用法
WO2021146625A1 (en) * 2020-01-17 2021-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gene therapy for treatment of crx-autosomal dominant retinopathies
US20230174598A1 (en) * 2020-03-18 2023-06-08 University Of Florida Research Foundation, Incorporated Modified arrestin-1 to enhance photoreceptor survival in retinal disease
CN111849998A (zh) * 2020-07-29 2020-10-30 武汉纽福斯生物科技有限公司 编码人卵黄状黄斑病蛋白1的核酸分子及其应用
JP2023548746A (ja) * 2020-10-13 2023-11-21 クリヤ セラピューティクス インコーポレイテッド サイトカインをコードする核酸を送達するためのウイルスベクターコンストラクトおよびがんを処置するためのその使用
CN113201556B (zh) * 2021-05-14 2022-11-22 浙江大学 pSOY19-ZM2载体、其制备方法及应用
WO2023280388A1 (en) * 2021-07-06 2023-01-12 Institute Of Molecular And Clinical Ophthalmology Basel Promoter for specific expression of genes in rod photoreceptors
CN115820653A (zh) * 2021-09-17 2023-03-21 深圳华大生命科学研究院 基因突变体及其应用
CN119432856B (zh) * 2024-12-30 2025-08-12 云舟生物科技(广州)股份有限公司 核酸分子、病毒颗粒及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100190841A1 (en) * 2007-04-12 2010-07-29 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabe Genetic suppression and replacement
WO2015020522A1 (en) * 2013-08-05 2015-02-12 Koninklijke Nederlandse Akademie Van Wetenschappen Recombinant aav-crumbs homologue composition and methods for treating lca-8 and progressive rp

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2760263T3 (es) * 2014-03-21 2020-05-13 Genzyme Corp Tratamiento génico de la retinitis pigmentaria
EP3210632B1 (en) * 2016-02-23 2022-09-28 EyeServ GmbH Gene therapy for the treatment of a retinal degeneration disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100190841A1 (en) * 2007-04-12 2010-07-29 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabe Genetic suppression and replacement
WO2015020522A1 (en) * 2013-08-05 2015-02-12 Koninklijke Nederlandse Akademie Van Wetenschappen Recombinant aav-crumbs homologue composition and methods for treating lca-8 and progressive rp

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Koch, S. et al., 'Gene therapy restores vision and delays degeneration in the CNGB1-/- mouse model of retinitis pigmentosa', Human Molecular Genetics, (2012-10-15), vol. 21, no. 20, pages 4486 - 4496, doi: 10.1093/hmg/dds290. *
May, L. et al., 'In vitro comparison studies of truncated rhodopsin promoter fragments from various species in human cell lines', Clinical and Experimental Ophthalmology, (2003-10-01), vol. 31, no. 5, pages 445 - 450. *
Paul, D. et al., 'Construction of a recombinant adeno-associated virus (rAAV) vector expressing murine interleukin-12 (IL-12)', Cancer Gene Therapy, (2000-02-01), vol. 7, no. 2, pages 308 - 315, doi: 10.1038/sj.cgt.7700105. *
Rehemtulla, A. et al., 'The basic motif-leucine zipper transcription factor Nrl can positively regulate rhodopsin gene expression', PNAS, (1996), vol. 93, pages 191-195. *

Also Published As

Publication number Publication date
US20250262328A1 (en) 2025-08-21
UY37636A (es) 2018-10-31
JP2020511167A (ja) 2020-04-16
US12246072B2 (en) 2025-03-11
JP7257377B2 (ja) 2023-04-13
EP3600446A1 (en) 2020-02-05
TW201902911A (zh) 2019-01-16
AU2018238422A1 (en) 2019-10-03
CA3056211A1 (en) 2018-09-27
WO2018172961A1 (en) 2018-09-27
AR111188A1 (es) 2019-06-12
US20200030458A1 (en) 2020-01-30
CN111050805A (zh) 2020-04-21

Similar Documents

Publication Publication Date Title
AU2018238422B2 (en) Gene therapy for the treatment of CNGB1-linked retinitis pigmentosa
KR102604159B1 (ko) 조직 선택적 트랜스진 발현
CN102918152B (zh) 用于治疗莱伯氏先天性黑蒙-1（lca1）的raav-鸟苷酸环化酶组合物及方法
KR102808368B1 (ko) 선택적 유전자 조절을 위한 조성물 및 방법
JP2023153788A (ja) １色覚および他の疾患の治療のためのプロモーター、発現カセット、ベクター、キット、ならびに方法
CN113544267A (zh) 使用CRISPR-Cas进行靶向核RNA裂解和聚腺苷酸化
KR20220098384A (ko) 폼페병 및 리소좀 장애를 치료하기 위한 간-특이적 프로모터를 포함하는 치료적 아데노-관련 바이러스
CN112312929A (zh) 用于包括线粒体dna耗竭综合征在内的由不平衡的核苷酸库引起的疾病的基因疗法
CN116685329B (zh) 核酸构建体及其用于治疗脊髓性肌肉萎缩症的用途
AU2020302081A1 (en) Modeling TDP-43 proteinopathy
KR20210132109A (ko) Dna-결합 도메인 전사활성화제 및 이의 용도
JP2021101713A (ja) 筋強直性ジストロフィーの処置
KR20240042363A (ko) 뇌전증을 치료하기 위한 방법 및 조성물
CN116390935A (zh) 核酸构建体、病毒载体和病毒颗粒
WO2024069144A1 (en) Rna editing vector
TW202421787A (zh) 保護心臟之心臟病療法
RU2825840C2 (ru) Мониторинг генной терапии
US20250381303A1 (en) Crispr interference therapeutics for c9orf72 repeat expansion disease
AU2018203034A1 (en) rAAV-guanylate cyclase compositions and methods for treating Leber's congenital amaurosis-1 (LCA1)
WO2025080779A2 (en) Methods and compositions for altering gene expression
CN116670159A (zh) 组合物及其用于治疗安格尔曼综合征的用途
Tan Development of gene therapy for the treatment of retinal dystrophies caused by mutations in AIPL1
Jiang RNA interference gene therapy for dominant photoreceptor degeneration disease in mouse models expressing mutant guanylate cyclase-activating protein 1

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)